MeSH D043183 - irritable bowel syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Salix Pharmaceuticals | Rifaximin | Xifaxan | 2024-06-19 | 2004-05-25 | ||
| Teva | Lubiprostone | Lubiprostone | 2022-01-18 | |||
| Mylan | Linaclotide | Linaclotide | 2021-02-09 | |||
| AbbVie | Linaclotide | Constella | 2012-11-26 | |||
| Linaclotide | Linzess | 2024-01-28 | 2012-08-30 | $1,115 M | Q2/23-Q1/24 | |
| Eluxadoline | Viberzi | 2025-03-14 | 2015-05-27 | |||
| Allergan | Eluxadoline | Truberzi | 2016-09-19 | |||
| Aurobindo Pharma | Linaclotide | Linaclotide | 2023-02-07 | |||
| Dr Reddys Laboratories | Lubiprostone | Lubiprostone | 2022-02-08 |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
65%13/20
Phase 2
51%23/45
Phase 3
64%27/42
Approved: 13Overall Success rate: 21%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use